Global Upfront Newspapers
Breaking News Cover Features Health News

India’s first needle-free 3-dose Coronavirus vaccine for 12+ ZyCoV-D is here: All you need to know about it

01/6All about India’s first needle-free COVID-19 vaccine

Covaxin was India’s first indigenous vaccine against COVID-19 and now we have the second indigenous jab which will soon be available across seven Indian states. What makes ZyCoV-D vaccine unique is that it is a needle-less jab which had earned authorization from the Drugs Controller General of India in August.

02/6It will also be eligible for 12-19 years

Right now the vaccine will only be administered to adults until it’s able to strengthen its production capacity. That’s when it will be extended to adolescents too, as per Dr Sandeep Patil, Chief Intensivist, Fortis Hospital, Kalyan.

03/6ZyCoV-D: India’s first needle-less vaccine

ZyCoV-D will be a needle-less vaccine which will be administered using a needle-free applicator instead of traditional syringes. It is a three-dose vaccine, whose second and third doses are to be taken 28 and 56 days after the first. As per reports, the single dose of the vaccine will be made available to the Centre at Rs 376 including the cost of the jet applicator and GST, taking the price of 3-dose jab to Rs 1,128.

The Zydus Cadila shot will not yet be a part of the national vaccination drive but will be available in seven states first, a top government official shared.

04/6ZyCoV-D is a DNA-plasmid vaccine

This is the first COVID-19 vaccine candidate developed on a plasmid DNA platform to be commercially introduced anywhere in the world. To understand what’s DNA-PLASMID vaccine, we need to understand that most vaccines are made using a weakened or killed form of the infectious agent. In this case, a piece of DNA containing the genes for the antigens is used to inject in the body. This helps the body to learn how to respond against the antigen. So when the pathogen attacks, the body can then generate specific antibodies to combat COVID.

05/6It has shown 66.66% efficacy in phase 3 trial

This was the first vaccine which was also tested in the adolescent population (12-18 years). The vaccine has been jointly developed in partnership with the Department of Biotechnology, showing a primary efficacy of 66.66% in phase 3 clinical trials. Putting aside storage concerns, the vaccine remains stable in room temperatures for three months, unlike mRNA vaccines which require ultra-cold storage systems.


Dr Sandeep Patil, Chief Intensivist, Fortis Hospital, Kalyan, shares that according to the data collected during this trial, this vaccine had already exhibited robust immunogenicity, tolerability and safety profile in the adaptive Phase I/II clinical trials carried out earlier. It said this vaccine works against the Delta variant as the trials have been carried out in more than 50 clinical sites spread across the country, and during the peak of the second wave of COVID19, have shown the vaccine’s efficacy against the new mutant strains, especially the Delta variant. Data also shows equivalent immunogenicity with that of the three-dose regimen. Therefore, a two-dose regimen approval is also expected. However, the expert panel will review more data on the same.

Originally published in Times of India,

Advertize With Us

See Also

Naira devaluation: BDCs get subsidized dollars at N393, sell for N494

Global Upfront

How Dr Chike Akunyili was killed by ‘Unknown Gunmen’ Tuesday night in Nkpor, Anambra State

Global Upfront

Kogi’s Yahaya Bello is North Central Governor who made N60 billion cash withdrawal from State coffers, says EFCC

Global Upfront

‘Dozens’ of ISWAP terrorists killed by NAF airstrikes at Doron Naira, on the fringes of Lake Chad, says Defence Spokesperson

Global Upfront

Nigeria’s COVID-19 cases rise to 254, with 44 discharged, six dead

Global Upfront

419: Dankofa has case to answer, Supreme Court decides

Global Upfront

For Unvaccinated, COVID Reinfection Is Likely – “Can Happen in Three Months or Less”

Global Upfront

Chairman Of The Party, By Uzor Maxim Uzoatu

Global Upfront

Insecurity: U.S. Advises Citizens To Limit, Avoid Movements Within FCT Abuja, Lists High, Low Risk Security Areas

Global Upfront

Speak Out, Act As Northern Nigeria Turns To ‘Arewanistan,’ Bishop Kukah Tells Buhari

Global Upfront

This website uses Cookies to improve User experience. We assume this is OK...If not, please opt-out! Accept Read More